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Summary
The phase III Transfusion and Treatment of severe anaemia in African
Children Trial (TRACT) found that conservative management of uncompli-
cated severe anaemia [haemoglobin (Hb) 40–60 g/l] was safe, and that
transfusion volume (20 vs. 30 ml/kg whole blood equivalent) for children
with severe anaemia (Hb <60 g/l) had strong but opposing effects on mor-
tality, depending on fever status (>375°C). In 2020 a stakeholder meeting
of paediatric and blood transfusion groups from Africa reviewed the results
and additional analyses. Among all 3196 children receiving an initial trans-
fusion there was no evidence that nutritional status, presence of shock,
malaria parasite burden or sickle cell disease status influenced outcomes or
modified the interaction with fever status on volume required. Fever status
at the time of ordering blood was a reliable determinant of volume
required for optimal outcome. Elevated heart and respiratory rates nor-
malised irrespective of transfusion volume and without diuretics. By con-
sensus, a transfusion management algorithm was developed, incorporating
three additional measurements of Hb post-admission, alongside clinical
monitoring. The proposed algorithm should help clinicians safely imple-
ment findings from TRACT. Further research should assess its implementa-
tion in routine clinical practice.
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Introduction
In sub-Saharan Africa, children admitted to hospital with
severe anaemia [defined as a haemoglobin (Hb) of <60 g/l]
present a major public health burden on in-patient and
blood transfusion services. Although timely transfusion is fre-
quently lifesaving, equitable access to adequate supplies of
safe blood remains a key challenge.1 In 2013 the World
Health Organization (WHO) Global Database on Blood
Safety reported that <5 units of blood were donated per
1000 people in most African countries,2 far fewer than esti-
mated requirements of 20 units/1000 per year.2 Despite con-
siderable investment by external funders in the decade since
their previous report (2004–2005),3 few countries had made
significant improvements in their collection rates.
Guidelines developed by the WHO encourage the conser-
vative use of blood in children, restricting routine transfusion
to those with severe anaemia, defined as an Hb <40 g/l, or
40–60 g/l with clinical signs of severity.4 However, the under-
pinning evidence base for this recommendation is weak5 and
adherence to these guidelines is poor,6,7 which is com-
pounded by inconsistent Hb threshold recommendations for
transfusion for malaria. Currently, 20 ml/kg of whole blood
(or 10 ml/kg of packed cells) is recommended for severe
anaemia.4 However, if standard formulae for transfusion vol-
ume were applied,8,9 the one-size-fits-all 20 ml/kg recom-
mendation would underestimate transfusion requirements by
~30%.6,10 A consensus international guideline on transfusion
of critically ill children also noted a weak global evidence
base and specifically highlighted the need to evaluate optimal
transfusion volumes.11
The Transfusion and Treatment of Severe Anaemia in
African Children Trial (TRACT) was designed as a multicen-
tre trial to establish transfusion and treatment strategies in
sub-Saharan Africa and investigated: (i) whether an immedi-
ate transfusion in children with uncomplicated severe anae-
mia (Hb 40–60 g/l) would improve outcomes and (ii)
whether 30 versus 20 ml/kg whole blood might improve out-
comes, defined as mortality to day 28 (primary outcome)
and day 180, and the need for additional transfusions and
relapse of severe anaemia.12
The trial results, published in two linked manuscripts in
2019,13,14 showed that an immediate transfusion is not
required in children with uncomplicated severe anaemia (Hb
40–60 g/l without severity features), as long as children are
monitored for progression to the development of severe and/
or complicated anaemia during their initial hospital stay; such
progression occurred in 49% of trial participants who then
received a transfusion.13 The results also showed that giving
larger volumes of blood, 30 ml/kg whole blood equivalent ver-
sus the 20 ml/kg recommended in the current WHO guideli-
nes, to children with severe anaemia who did not have a fever
(axillary temperature ≤375°C, measured at screening) halved
the number of deaths by 28 days [hazard ratio (HR) 043,
95% confidence interval (CI) 027–069].14 However, the
opposite occurred in children who were febrile (>375°C) at
screening; 30 ml/kg whole blood equivalent almost doubled
the risk of death in comparison to children who received the
lower, 20 ml/kg, volume (HR 191, 95% CI 104–349; P value
for heterogeneity of effect on mortality P = 000009).
The TRACT results provide an evidence base with poten-
tial to improve outcomes for children with severe anaemia.
Furthermore, initial economic analyses also suggested that if
the results were implemented and adhered to by clinicians,
there could be substantial cost savings for blood transfusion
services. To explore this further, the TRACT investigators
shared results from the trial with key stakeholders at a meet-
ing in Uganda in February 2020, co-hosted by the African
Society for Blood Transfusion and the Ugandan Paediatric
Association. The meeting was attended by stakeholders from
12 sub-Saharan countries and included representatives from
blood transfusion services, health service providers (including
paediatricians involved in providing continued professional
development and training courses) and representatives from
international policymakers, including the WHO and
Medecins Sans Frontieres (Appendix 1). Our aim was to clar-
ify current practice in different settings within Africa, to dis-
cuss the implications of the TRACT findings from a
stakeholder perspective, to identify potential barriers to their
uptake and to identify any additional requirements that
might be needed to support their safe implementation,
including further analyses of the TRACT data.
A major output from discussions at this stakeholder meet-
ing was the development of a transfusion management algo-
rithm for future implementation, which was agreed by
consensus. Here, we present the algorithm and the additional
analyses that support it.
Methods
A summary of the trial and statistical methods is available in
the supplemental appendix. Blood transfusions were supplied
by the local blood transfusion services (BTS), which included
three blood component types: (i) whole blood (WB), col-
lected from donors and stored without any preparation or
via transfer bags into smaller bags of whole blood (known as
‘Pedi-Packs’); (ii) packed red cell concentrates (RCC), pro-
duced by centrifugation to remove platelets and plasma, fol-
lowed by the addition of sodium, adenine, glucose and
mannitol solution; and (iii) RCC created using gravity
(Uganda only).15 To support the algorithm, we investigated
detailed response to transfusion volume and requirement for
additional transfusions. At the request of participants at the
meeting we provided original and further analyses of the pri-
mary outcome (28-day mortality) in the following key sub-
groups: (i) nutritional status (protocol defined); (ii) malaria
status including those with high malaria burdens (plasma
Plasmodium falciparum histidine-rich protein 2 (PfHRP2)
concentration of >1000 ng/ml16); (iii) children with shock
defined by the Fluid Expansion As Supportive Therapy in
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critically ill African children (FEAST) trial eligibility crite-
ria;17 and those with sickle cell disease (SCD). These sub-
groups all have direct implications for the current WHO
management guidelines.4 Finally, additional exploration of
the fever/no fever interaction was undertaken for a number
key subgroups where the interaction might potentially have
been impacted for physiological reasons [including SCD and
Blackwater fever (haemoglobinuria)].18
Results
The TRACT recruited children aged 2 months to 12 years
presenting to hospital with both uncomplicated and compli-
cated severe anaemia (Fig 1), and the algorithm is aimed at
this population (Fig 2). We found no evidence to show that
outcome was affected by nutritional status (including children
classified as undernourished) or by SCD status (which was
unknown at the time of randomisation in the majority) (Fig
3A). In the current WHO guidelines, malaria hyperpara-
sitaemia is an indicator for immediate transfusion.4 We there-
fore assessed whether this was supported by the TRACT.
Instead of ‘hyperparasitaemia’, we used the value PfHRP2
≥1000 ng/ml, a parameter that more accurately reflects the
highest total parasite burden, and which distinguishes ‘true’
severe malarial anaemia from anaemia in the presence of inci-
dental parasitaemia.16 We found that outcome was the same
in children managed on a deferred transfusion protocol as in
those receiving immediate transfusion (Fig 3A). Thus, in our
algorithm we did not provide separate recommendations with
regard to immediate or deferred transfusion for these groups.
For the higher versus lower volume comparison, the stake-
holder meeting group identified two subgroups that could,
potentially, have increased the risk of a worse outcome with
higher transfusion volumes, irrespective of fever status: (i)
children with clinical features of shock (severely impaired per-
fusion as defined in FEAST trial17); and (ii) children with
anthropometric features of undernutrition. As shown in Fig
3B none of these subgroups had outcomes that differed sig-
nificantly from the overall findings. Therefore, the stakeholder
meeting concluded that the recommendations on transfusion
volume did not need to differ according to a child’s perfusion
status, nutrition status or malaria parasite burden.
The initial evaluation of a child with suspected severe anae-
mia should include a Hb test, axillary (or other) temperature,
weight and assessment for severity signs (altered conscious
level or respiratory distress). Then the child can be grouped
into one of three categories: (i) severe and complicated anae-
mia (Hb <40 g/l or Hb 40–60 g/l, with clinical severity fea-
tures); (ii) Hb 40–60 g/l, without clinical severity features; and
(iii) Hb >60 g/l, with or without severity signs. The first group
require immediate transfusion; the second group do not
require immediate transfusion but should have a blood sample
sent to the transfusion services for blood ABO grouping19 and
blood unit(s) (WB or RCC) saved while being monitored both
clinically and for Hb level (at a minimum of 8, 24 and 48 h
following identification). The volume for transfusion, based
on weight and temperature can be obtained from Table I. The
third group does not require transfusion (with Hb >60 g/l)
and can be managed without further Hb monitoring (Fig 2).
Once children have been transfused, or for stable children
with Hb 40–60 g/l, they will continue to be monitored and
further transfusion management will depend on their latest
Hb and/or clinical features.
Blood volume dosing table
In the TRACT, we were reassured that >96% of children
received the correct volume of blood. Children weighed
between 5 and 35 kg, the majority (~75%) weighing ≤15 kg.
Thus, most of the WB prescriptions for the 20 ml/kg strategy
were between 100 and 320 ml and for the 30 ml/kg strategy
were between 150 and 480 ml. To simplify future implemen-
tation of the algorithm, we have generated a simplified ‘look-
up’ chart together with bag size recommendations for WB
Pedi-Packs for appropriate weight bands (Table I Blood dos-
ing chart). If WB is unavailable then the equivalent RCC
doses are half the doses stated in the ‘look-up’ chart. This is
intended to be used alongside the transfusion algorithm.
Timing and stability of fever
For children with severe or complicated anaemia, the volume
of blood component ordered (20 or 30 ml/kg WB) in the
algorithm is dependent on the axillary temperature at the time
of requesting blood. For those with uncomplicated anaemia
that subsequently need a transfusion, the axillary temperature
at the time of ordering blood would be used. In the TRACT
trial nearly all children (3106/3196, 972%) had a history of
fever in the current illness, but only 1253 (392%) had a
recorded fever at screening, before the receipt of a transfusion.
Screening temperature is only at one time point, so we exam-
ined the patterns of fever during their hospital stay and found
only 10% of children without a fever at screening developed
one after the transfusion had started. For children with a fever
at screening, the fever had waned in 80% by 16 h (Fig 5). The
heterogeneity in the estimate of mortality remained for groups
defined by their fever status over 8 h (Fig 5; Figure S2) with
benefit from 30 ml/kg for those with no fever at screening,
even if they had intermittent fever during the subsequent 8 h.
However, if a child subsequently required new or additional
transfusion then the group recommended that the axillary
temperature at the time of requesting blood would be used to
indicate volume required, rather than the initial fever status at
initial screening.
What might be the mechanisms for excess mortality in
children receiving 30 ml/kg with fever?
We found no strong evidence implicating any specific cause
for the excess mortality associated with fever and blood
Transfusion Management of Severe Anaemia in African Children
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volume. Neither known SCD nor haemoglobinuria at admis-
sion had any effect on the fever/transfusion volume interac-
tion, nor did the age of the child (Figure S1). Transfusion-
related volume overload [pulmonary oedema, transfusion-re-
lated lung injury (TRALI) or transfusion-associated cardiac
overload (TACO)] was ruled out because of the small
Fig 1. Transfusions given in the TRACT trial.
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number of solicited events (n = 5) in the trial (summarised
in Table SI); only one was adjudicated to be probably related
to blood volume. No child received diuretics or other anti-
failure medications. The recovery of elevated heart and respi-
ratory rates occurred similarly in both febrile and afebrile
groups (Figure S3). Blood component type (WB or RCC)
was also explored in a pre-planned sub-analysis of the
TRACT and was found not to have contributed to adverse
outcomes. The stakeholders supported the algorithm recom-
mending both 30 and 20 ml/kg transfusion WB volumes (or
RCC equivalent), depending on fever status.
Children in the no immediate transfusion category: what
triggered transfusion and when was it given?
Children with uncomplicated severe anaemia (no severity
signs and Hb 40–60 g/l) would be monitored clinically
according to the algorithm, with a Hb test at 8, 24 and 48 h
and not transfused unless they develop severity signs or Hb
<40 g/l. In the TRACT trial 386/787 (49%) children ran-
domised to not receive an immediate transfusion, subse-
quently did receive one; details of timing of triggered
transfusions are in Figs 1 and 4A. Haemodilution, by liberal
use of intravenous fluids, was discounted, based on the fact
Fig 2. Algorithm for managing suspected/confirmed severe anaemia.
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a
b
*Severe illness: respiratory distress or impaired consciousness. Impaired perfusion: one or more of the following: capillary refill >2s, temperature 
gradient, weak pulse or severe tachycardia. 293 children were not febrile at admission but had history of fever, severe illness and impaired perfusion and 
so are included in the eligible group. 
aUndernourished: one or more of as mid-upper arm circumference (MUAC) ≥ 11·0cm – 11.9cm (children aged 2 to 6 months) or MUAC ≥ 11·5cm – 12.4 
(children aged 6 months to 59 months) or WHZ-3 to -2 (or WAZ if height not recorded) at any age. 
bMalnourished: one or more of mid-upper arm circumference (MUAC) < 11·0cm (children aged 2 to 6 months) or MUAC < 11·5cm (children aged 6 to 59 






Fig 3. (A) Morality at 28 days by subgroups for the immediate vs control timing of transfusion comparison. (B) Morality at 28 days by sub-
groups for the transfusion volume comparison. PfHRP2, plasma Plasmodium falciparum histidine-rich- protein 2.
K. Maitland et al.
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that no fluid boluses were given17 and children only received
maintenance fluids until they were able to drink. Compared
to children randomised to immediate transfusion, who
received blood at a median [interquartile range (IQR)] of
13 [09–17] h after randomisation, 295/386 (76%) of those
in the deferred group received a subsequent transfusion,
principally triggered by a fall in Hb to <40 g/l, at a median
(IQR) of 249 (92–498) h after randomisation. Reasons for
transfusion in an additional 57 (15%) children were the
development of clinical severity features (impaired conscious-
ness or increased work of breathing) and SCD identified in
hospital (n = 7; 2%). Only 27 (7%) had a transfusion with-
out a very low Hb or a recorded severity feature, largely after
48 h when reasons for transfusion were not routinely cap-
tured. Of note, the timing of triggered transfusions largely
coincided with the routine Hb assessment in the trial (at 8,
16, 24 and 48 h after randomisation) and 49% were given
within 24 h (excluding the 24 assessment) (Fig 4A). A fur-
ther two Hb measurements (at 36 and 48 h) would have
identified around two-thirds (249/386; 645%) of children in
the control group who subsequently received a transfusion.
Thus, this informed the recommendation in the algorithm
for repeat Hb measurements at 8, 24 and 48 h (Fig 2), with
additional measurements at 16 and 36 h where resources
permit.
Timing of deaths in controls: concern that this may be
related to delaying transfusion
Of the 13 children in the control arm who died, 10 had
received a transfusion prior to death and these were received
at a median of 9 h after randomisation.13 Furthermore, of
seven children transfused before 10 h, one died on Day 1
(who had a screening Hb of 59 g/l) and six died between
days 4–23, with a recorded 48-h Hb level of 50–90 g/l (only
two were <60 g/l). Three were not transfused; one died on
day 1 with last recorded Hb of 46 g/l, while two died on day
6 and day 25 with 48-h Hb levels of 54 and 65 g/l respec-
tively. In summary, delay in transfusion or no receipt of
transfusion does not appear to have made a clear contribu-
tion to outcome among these deaths (Supplemental material
original report).13
In children requiring additional transfusions: what
triggered re-transfusion events and when were they
given?
In the TRACT trial, of those receiving immediate transfusion,
3188/3196 (99%) received one, and 496/3196 (155%)
received a second transfusion, 300 (19%) in the 20 ml/kg
group and 196 (12%) in the 30 ml/kg group, an absolute dif-
ference of 6% (95% CI 4–9%, P < 00001) greater in the
20 ml/kg strategy.14 Overall, re-transfusions were due to falls
in Hb to <40 g/l in 185 (37%) children, and occurred more
frequently in the 20 ml/kg group (42% vs. 30% in 30 ml/kg
group) (Table II), or it was felt that clinically stable children
with SCD or haemoglobinuria with Hb between 40 and
60 g/l needed it corrected to >60 g/l (n = 206, 42%). The
number for which an Hb <40 g/l prompted the second trans-
fusion supports our recommendation in the algorithm for
repeat Hb measurements at 8, 24 and 48 h among children
who have been transfused, as well as those being monitored
before a possible transfusion. These three additional mea-
surements capture the large proportion of repeat transfu-
sions, as very few received an additional transfusion for new
clinical signs of severity after admission (2%) or when Hb
was >60 g/l (Fig 1). With regard to the timing of additional
transfusions, they occurred earlier and at a higher rate in
those randomised to 20 ml/kg. Approximately 5% of chil-
dren in this group received a transfusion by 24 h and 9–10%
by 48 h, compared to under half this rate at both time points
in the 30 ml/kg arm (Fig 4B). Although it was the second
most common reason for a second transfusion, SCD status
(known or unknown) was not a risk factor for poor out-
come, this group was not segregated in the algorithm for
repeat transfusion.
Consensus blood transfusion algorithm
Following discussion of all of the above, the meeting partici-
pants endorsed the proposed paediatric blood transfusion
algorithm based on the evidence provided by the TRACT
(Fig 2). The key elements start with triage of a child with
suspected severe anaemia, incorporating an assessment of
severity (to determine the need for a transfusion), with fur-
ther management guided initially by an assessment of Hb (or
haematocrit if Hb is not possible) and fever status at the
time a blood transfusion is ordered from the blood transfu-
sion service, in order to determine whether to request a
higher volume of blood (30 ml/kg WB or 15 ml/kg RCC), or
standard volume (20 ml/kg WB or 10 ml/kg RCC) if fever is
present. Informed by the main time points when first (for
children with uncomplicated anaemia) or repeat transfusions
occurred, our proposed algorithm also incorporates a mini-
mal number of additional measurements of Hb (or haemat-
ocrit) and clinical monitoring.
Discussion
If fully implemented, our proposed paediatric blood transfu-
sion algorithm could avert the need for immediate transfu-
sion in children with severe uncomplicated anaemia
(including those with SCD) and provide higher volumes of
blood to children with severe and complicated anaemia
(based on clinical signs and severity of anaemia) who do not
have a fever. Both these strategies would improve clinical
outcomes, more specifically, in children without a fever, a
liberal 30 ml/kg strategy would result in almost 60% fewer
children dying, while for children with a fever a conservative
20 ml/kg strategy would prevent a 50% higher mortality were
K. Maitland et al.
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(A)
(B)
Fig 4. (A) Time to Transfusion in Immediate vs Control Comparison. (B) Cumulative incidence in second transfusion in the 30 mls/kg vs. 20
mls/kg split by fever and no fever. Note: A competing risks analysis with discharge, absconding and death as competing events. There are 39
transfusions given after 120 h from baseline not included on the graph. [Colour figure can be viewed at wileyonlinelibrary.com]
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they to receive the higher volume. Although more complex,
the TRACT showed that this approach could substantially
reduce the demand for paediatric transfusion because the
higher volumes given to children without fever would also
significantly reduce the number of additional transfusions
required. Our previous cost-effectiveness analysis indicated
substantial savings for health services, with 60% reduction in
blood transfusion required compared to immediate transfu-
sion for all children with uncomplicated severe anaemia (Hb
<60 g/l).13 The unadjusted cost-effectiveness analyses, pre-
sented in the trial reports, demonstrated that the ‘no imme-
diate transfusion strategy’ would cost $6646 (American
dollars) per child in comparison to $7209 per child for an
immediate transfusion strategy: the Meeting attendants
recognised that the cost savings would be even greater where
per-unit costs of donor blood are higher.
It was recognised that implementation of the algorithm in
a real-life setting is required, in order to establish feasibility,
NB: excludes children who died prior to 8 hours (n=36) and 1 child that absconded. Time at risk from 8 hours onwards.
Fig 5. Justification for transfusion volume management based on initial temperature and not on subsequent temperatures.
Table II. What were the indications for second transfusions by volume randomisation and by fever status?
Second transfusions for those randomised to transfusion arms, n (%)




fever* (n = 123)
20 ml without
fever (n = 177)
30 ml with
fever* (n = 83)
30 ml without
fever (n = 113)
New Hb <40 g/l 185 (37) 45 (37) 82 (46) 18 (22) 40 (35)
New severity signs‡ and Hb 40–60 g/l 9 (2) 3 (2) 1 (<1) 2 (2) 3 (3)
Known SCD or haemoglobinuria
and Hb 40–60 g/l
206 (42) 56 (46) 63 (36) 37 (45) 50 (44)
Not per protocol§ 96 (19) 19 (15) 31 (18) 26 (31) 20 (18)
Hb, haemoglobin; SCD, sickle cell disease.
*Axillary temperature ≥375°C.
†497 transfusions were reported in the original trial paper but following publication it was found that one of those transfusions was of a negligi-
ble amount.14
‡Severity sign (impaired consciousness and or increased work of breathing).
§No recorded severity signs (impaired consciousness or increased work of breathing), no SCD or haemoglobinuria and Hb ≥40 and <60 g/l.
K. Maitland et al.
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impact on mortality and whether it reduces unwarranted
requests for paediatric transfusions. However, most paediatri-
cians felt that the proposed recommendations for Hb moni-
toring could be a substantial hurdle for clinical services in
some resource-limited hospitals (see accompanying Perspec-
tive Paper). As demonstrated in the cost-effectiveness models,
major costs to health services are the ‘hotel costs’ (days in
hospital) and the price of a blood transfusions. Total costs
could be reduced by access to 24-h point-of-care Hb mea-
surements, which would require advocacy to the health ser-
vices and policy makers from both paediatricians and blood
transfusion services.
The strengths of the TRACT trial include its size, multi-
centre nature (Uganda and Malawi), broad eligibility criteria
that enhances its generalisability and enables incorporation
of large subgroups with malaria and SCD. In children with
uncomplicated severe anaemia, we found a large group of
children with undiagnosed SCD. We found no evidence that
not transfusing these children (as they did not develop sever-
ity features or profound anaemia) resulted in a worse out-
come (mortality to Day 28 and Day 180). On this basis,
children with either diagnosed or undiagnosed SCD without
severity features can be safely managed using a triggered
transfusion strategy and thus incorporated into the algo-
rithm.
As noted by the meeting stakeholders most transfusions in
the TRACT were given very shortly after screening/identifica-
tion of a case of severe anaemia (when axillary temperature
was recorded), which may not be replicable in usual clinical
practice. The relevance of a temperature taken hours before a
blood transfusion becomes available was explored by addi-
tional analyses. These supported the recommendation that at
the time that blood is ordered for a child who has no fever
at that time, even if they subsequently developed an intermit-
tent fever (Fig 5), it was still safe (and beneficial) to transfuse
with a higher volume. Similarly, for children who have a
fever at the time blood is ordered and which then wanes,
there is no evidence to support that the requested 20 ml/kg
volume would lead to any difference in outcome compared
to 30 ml/kg. For children with a persistent fever prescribing
20 ml/kg is also supported by these analyses.
Conclusions
The new evidence provided by the TRACT could lead to
important refinements of the WHO transfusion guidelines.
First, standardising the definition of severe anaemia, we sug-
gest an Hb <60 g/l. Second, clarifying the definitions of
uncomplicated severe anaemia, and severe and complicated
anaemia, by using clinical signs of severity. Third, a strong
recommendation (based on high quality of evidence) that
children with uncomplicated severe anaemia do not require
immediate transfusion, irrespective of the underlying causes,
but do require monitoring because ~50% will develop severe
and life-threatening anaemia requiring subsequent
transfusion. Fourth, new recommendations to include a min-
imal number of clinical and Hb monitoring reviews in a
child with severe anaemia (both uncomplicated and compli-
cated) in order to identify those needing an initial or addi-
tional transfusion. Fifth, new recommendations on the
volume of blood to transfuse, according to fever status when
a blood transfusion is ordered, and that either WB or packed
RCC (at half the volume) can be used. Finally, the guidelines
should make it clear that there is no need for separate rec-
ommendations for children with malaria (even those with
high parasite burdens), SCD or poor nutritional status. As
the trial demonstrated, a high proportion of children pre-
senting with severe anaemia in many of our present study
sites had undiagnosed SCD. The group recommended, there-
fore, that admission to hospital with severe anaemia should
prompt clinicians to test for SCD so that long-term follow-
up and infection prophylaxis can be put in place.
Funding
The meeting was funded by Imperial College, London, UK
though an internally managed Research England Global
Challenges Research Funding Scheme (2019–2020). The
TRACT trial was Supported by a grant (MR/J012483/1) from
the United Kingdom Medical Research Council (MRC)
through a concordat with the Department for International
Development. The MRC Clinical Trials Unit at University
College London receives core support from the MRC
(MC_UU_12023/26).
Patient and Public Involvement
Patients and public were not involved in the meeting or the
interpretation of the results and development of the transfu-
sion algorithm. We thank all the participants and their fami-
lies, and staff from all the centres participating in the
TRACT trial.
Supporting Information
Additional supporting information may be found online in
the Supporting Information section at the end of the article.
Fig S1. Transfusion volume 30 versus 20 ml/kg compar-
ison by fever status at screening and sickle cell disease status.
Fig S2. Stability of temperature following screening/ran-
domisation.
Fig S3. Heart rate and respiratory rate over time from
beginning of first transfusion.
Table SI. Suspected overload events: endpoint review.
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Appendix 1
Full list of Stakeholder Meeting Attendees
Name Organisation Role Country
Dr Deogratias Munube Mulago Hospital President UPA Uganda
Dr Bodo Bongomin WHO Uganda WHO Technical Officer Uganda
Dr Eva Nabawanuka Mulago National Referral Hospital Study co-ordinator Uganda
Dr Robert Opoka Mulago Hospital Co-PI TRACT trial Uganda
Prof Peter Olupot Olupot Mbale Regional Referral Hospital Co-PI TRACT trial Uganda
Dr Florence Aloroker Soroti RRH Co-PI TRACT trial Uganda
Prof Philippa Musoke MUJHU TRACT DSMB Uganda
Dr Ritah Nasiima St Francis Hospital Nsambya Treasurer UPA Uganda
Prof Kathryn Maitland KEMRI Wellcome Trust Research
Programme
PI TRACT trial Kenya
Hellen Mnjalla KWTRP TRACT trial manager Kenya
Christabel Mogaka KWTRP Data Manager Kenya
Prof Thomas Williams KWTRP TRACT co-investigator Kenya
Dr Abubakarr Bah Ola During Children’s Hospital,
Freetown
Head of Paediatrics Emergency Unit Sierra Leone
Prof Elizabeth Molyneux Liverpool School of Tropical Medicine TSC Chair/ ETAT Lead UK
Dr Christian Umuhoza Secretary-General Rwanda Paediatric Association Rwanda
Dr William K. A. Obeng Korle Bu Teaching Hospital Accra ETAT Trainer Ghana
Dr Charlyne Kilba Korle BU Teaching Hospital, Accra Critical care specialist Ghana
Dr John Appiah Paediatric Critical care Senior specialist Ghana
Dr Ismail Ticklay ETAT Harare Zimbabwe
Dr Yamikani Chimalizeni UNIMA College of Medicine TRACT trial Investigator Malawi
Prof Russel Ware Cincinnati Children’s Hospital Sickle cell disease Specialist United States
Dr Roberta Petrucci Medicines Sans Frontiere International Paediatric Working Group Geneva
Prof Diana Gibb MRC Clinical Trials Unit at UCL Professor of Epidemiology UK
Prof Sarah Walker MRC/CTU at UCL Professor of Medical Statistics and Epidemiology UK
Annabelle South MRC/CTU at UCL Policy and Research Impact Co-ordinator UK
Prof Dora Mbanya African Society for Blood
Transfusion (AfSBT)
AfSBT President Cameroon
Dr Sophie Uyoga KWTRP TRACT trial Investigator Kenya
Dr Bridon Mbaya Malawi Blood Transfusion Service (BTS) Medical Director Malawi
Dr ET Mberi Zimbabwe National BTS Director National Blood Transfusion Centre Zimbabwe
Dr Dorothy Kyeyune Uganda BTS Director Uganda
Dr Claude T. Tagny Haematology and Transfusion Service,
University of Yaounde
Director National Blood Transfusion Centre Cameroon
Dr Saliou Diop Senegal BTS Director National Blood Transfusion Centre Senegal
Dr Faten Moftah AfSBT AfSBT member Egypt
Dr Michael E. Acquah Ghana BTS Director Ghana
Prof Philip Olatunji AfSBT Professor of Haematology/Vice President, AfSBT Nigeria
Dr Magdalena Lyimo Tanzania BTS Director Tanzania
Prof Ludovic Anani Benin BTS Former manager, Blood Transfusion Agency of Benin Benin
Dr Shirley O. Ofori Kumasi BTS Director Ghana
Dr Charles Engoru Soroti RRH TRACT trial investigator Uganda
Prof Imelda Bates Liverpool School of Tropical Medicine TRACT trial investigator UK/TRACT trial
AfSBT, Africa Society for Blood Transfusion; BTS, blood transfusion services; CTU, Clinical Trials Unit; DSMB, Data and Safety Monitoring
Board; ETAT, Emergency Triage Assessment and Treatment; KWTRP, Kenya Medical Research Institute Wellcome Trust Research Programme;
MRC, UK Medical Research Council; MSF, Medecins Sans Frontieres; MUJHU, The Makerere University - Johns Hopkins University Research
Collaboration; PI, principal investigator; RRH, Regional Referral Hospital; STM, School of Tropical Medicine; TRACT, Transfusion and Treat-
ment of severe anaemia in African Children Trial; TSC, Trial Steering Committee; UNIMA, University of Malawi; UPA, Uganda Paediatric Asso-
ciation; WHO, World Health Organization.
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